Four years after receiving Hemgenix in a Phase 3 trial, bleeding rates and the use of replacement therapy are low for men ...

CSL Behring has shared positive four-year results from a late-stage study of its haemophilia B gene therapy Hemgenix ...

The study shows that 94% of patients eliminated factor IX prophylaxis and maintained near-normal factor IX levels through ...

CSL Behring's gene therapy Hemgenix four years post-infusion data continue to show sustained efficacy and safety in adults with haemophilia B: King of Prussia, Pennsylvania Monday ...

CSL (ASX: CSL; USOTC: CSLLY) has unveiled four-year results from its pivotal HOPE-B study, demonstrating the long-term ...

CSL and uniQure's Hemgenix shows sustained efficacy in hemophilia B, reducing bleeding rates by 90% and eliminating ...

Data from the study showed that HEMGENIX continues to deliver sustained factor IX activity levels for up to four years post-treatment. The treatment also provides long-term bleed protection, ...

Fidanacogene elaparvovec is a novel, investigational vector containing a bio-engineered adeno-associated virus capsid and a high-activity human coagulation factor IX gene. A lack of the gene ...

Sign up for Chalkbeat’s free weekly newsletter to keep up with how education is changing across the U.S. President Donald Trump’s administration told schools ...

The Department of Education announced Friday it is scrapping former President Biden’s 2024 Title IX changes, getting rid of discrimination protection based on gender identity and sexual ...

which involves introducing a functional copy of the faulty gene into the patient’s cells, thereby encouraging the production of factor IX in the body. This revolutionary approach not only improves ...